Adamas Pharmaceuticals, Inc. ADMS
Set alert
8.22 +8.22 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -22.22
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2021
- 50-d avg
- 7.00
- 200-d avg
- 5.54
- 1y target
- 8.52
Analyst view
Consensus: hold
Hold
Price target (mean) 8.52 +3.6% upside
Now 8.22
- Target (low)
- 8.00
- Target (mean)
- 8.52
- Target (high)
- 9.10
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 9
- 3 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.18 | -0.26 – -0.10 | -0.64 | +71.9% | 28.15M | +34.0% | 8 |
| Next quarter | -0.13 | -0.18 – -0.08 | -0.36 | +63.9% | 30.40M | +57.4% | 2 |
| Current year | -1.03 | -1.22 – -0.88 | -2.03 | +49.3% | 94.70M | +27.2% | 7 |
| Next year | -0.37 | -0.75 – 0.41 | -1.03 | +64.1% | 127.11M | +34.2% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2021 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Oct 12, 2021 | Piper Sandler | Downgrade | Overweight | Neutral |
| Oct 12, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Oct 11, 2021 | William Blair | Downgrade | Outperform | Market Perform |
| Jun 7, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Dec 17, 2019 | Cantor Fitzgerald | Reiterated | — | Neutral |
| Sep 30, 2019 | Bank of America | Downgrade | Neutral | Underperform |
| Sep 9, 2019 | Cantor Fitzgerald | Initiated | — | Neutral |
| Mar 5, 2019 | Needham | Downgrade | Buy | Hold |
| Mar 5, 2019 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Mar 5, 2019 | Mizuho | Downgrade | Neutral | Underperform |
| Nov 13, 2018 | Leerink Swann | Initiated | — | Outperform |
| Nov 5, 2018 | Mizuho | Downgrade | Buy | Neutral |
| Oct 5, 2018 | Bank of America | Downgrade | Buy | Neutral |
| Jul 16, 2018 | H.C. Wainwright | Initiated | — | Buy |
| Mar 27, 2018 | Bank of America | Initiated | — | Buy |
| Oct 30, 2017 | Evercore ISI Group | Initiated | — | Outperform |
| Aug 25, 2017 | JMP Securities | Maintained | — | Market Outperform |
| Apr 1, 2016 | JMP Securities | Initiated | — | Market Outperform |
| Jan 19, 2016 | Cowen & Co. | Initiated | — | Outperform |
| Jan 19, 2016 | Mizuho | Initiated | — | Neutral |
| Sep 22, 2015 | Aegis Capital | Initiated | — | Buy |
| Nov 7, 2014 | Credit Suisse | Maintained | — | Outperform |
| May 5, 2014 | Needham | Initiated | — | Buy |